TEVA - Generic Drug Player Teva Pharma To Divest Its Active Pharmaceutical Ingredient Business Q4 Earnings Surpass Estimates | Benzinga
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported fourth-quarter 2023 sales of $4.46 billion, beating the consensus of $3.99 billion.
This increase was mainly due to an upfront payment of $500 million in connection with the collaboration on anti-TL1A asset, the sale of certain product rights, higher revenues from generic products in the International Markets segment and Austedo, partially offset by lower revenues from generic products in North America segment and Copaxone.
The company reported fourth-quarter adjusted EPS of $1.00, higher than ...